$PULM
Pulmatrix Inc Stock $pulm

$pulm Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-K Financial Statement

#000119312519043624 Filed on February 19, 2019

Income Statement

Concept	2019 Q1	2018 Q4	2018
Revenue	$0.00	$153.0K	$153.0K
YoY Change	-100.0%		-54.33%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.990M	$1.590M	$7.520M
YoY Change	-2.93%	-13.59%	-0.66%
% of Gross Profit
Research & Development	$2.176M	$3.221M	$12.97M
YoY Change	-32.44%	24.36%	26.58%
% of Gross Profit
Depreciation & Amortization	$50.00K	$50.00K	$231.0K
YoY Change	-16.67%	-16.67%	-6.1%
% of Gross Profit
Operating Expenses	$4.957M	$5.267M	$20.55M
YoY Change	-5.89%	18.89%	15.4%
Operating Profit	-$4.957M	-$5.114M	-$20.40M
YoY Change	-3.07%		16.74%
Interest Expense	$0.00	$106.0K	$186.0K
YoY Change	-100.0%	-206.0%	-71.07%
% of Operating Profit
Other Income/Expense, Net	$1.000K	-$1.000K	-$163.0K
YoY Change	-200.0%		-71.94%
Pretax Income	-$5.160M	-$4.340M	-$20.56M
YoY Change	-1.15%	-3.98%	13.87%
Income Tax
% Of Pretax Income
Net Earnings	-$5.156M	-$5.221M	-$20.56M
YoY Change	-1.24%	15.51%	13.88%
Net Earnings / Revenue		-3412.42%	-13439.87%
Basic Earnings Per Share
Diluted Earnings Per Share	-$743.5K	-$869.7K	-$4.978M
COMMON SHARES
Basic Shares Outstanding	8.028M	46.93M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q1	2018 Q4	2018
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.150M	$2.560M	$2.560M
YoY Change	38.71%	-27.89%	-27.89%
Cash & Equivalents	$2.146M	$2.563M	$2.560M
Short-Term Investments
Other Short-Term Assets	$1.230M	$720.0K	$720.0K
YoY Change	251.43%	2.86%	2.86%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$3.382M	$3.280M	$3.280M
YoY Change	64.81%	-22.75%	-22.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$354.0K	$394.0K	$390.0K
YoY Change	-36.1%	-35.83%	-36.07%
Goodwill	$10.05M	$10.85M
YoY Change	-7.91%	-0.63%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$200.0K	$200.0K	$200.0K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$10.61M	$11.44M	$11.44M
YoY Change	-9.11%	-2.46%	-2.47%
TOTAL ASSETS
Total Short-Term Assets	$3.382M	$3.280M	$3.280M
Total Long-Term Assets	$10.61M	$11.44M	$11.44M
Total Assets	$13.99M	$14.72M	$14.72M
YoY Change	1.95%	-7.85%	-7.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.611M	$1.183M	$1.180M
YoY Change	35.15%	158.86%	156.52%
Accrued Expenses	$2.184M	$1.696M	$1.700M
YoY Change	-11.9%	-21.55%	-21.3%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%
Long-Term Debt Due		$0.00
YoY Change		-100.0%
Total Short-Term Liabilities	$3.795M	$2.879M	$2.880M
YoY Change	-38.75%	-50.7%	-50.68%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$0.00	$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.795M	$2.879M	$2.880M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$3.800M	$2.879M	$2.880M
YoY Change	-38.71%	-50.71%	-50.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$199.7M	-$194.6M
YoY Change	11.44%	11.82%
Common Stock	$209.9M	$206.4M
YoY Change	12.4%	12.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.20M	$11.84M	$11.84M
YoY Change
Total Liabilities & Shareholders Equity	$13.99M	$14.72M	$14.72M
YoY Change	1.95%	-7.85%	-7.88%

Cashflow Statement

Concept	2019 Q1	2018 Q4	2018
OPERATING ACTIVITIES
Net Income	-$5.156M	-$5.221M	-$20.56M
YoY Change	-1.24%	15.51%	13.88%
Depreciation, Depletion And Amortization	$50.00K	$50.00K	$231.0K
YoY Change	-16.67%	-16.67%	-6.1%
Cash From Operating Activities	-$3.456M	-$4.160M	-$16.76M
YoY Change	10.59%	29.6%	15.78%
INVESTING ACTIVITIES
Capital Expenditures	$10.00K	-$10.00K	$19.00K
YoY Change		-66.67%	-74.32%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$10.00K	-$10.00K	-$19.00K
YoY Change		-66.67%	-74.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$2.500M		$3.700M
YoY Change	35.35%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.049M	2.930M	15.79M
YoY Change	170.3%	565.91%	13.46%
NET CHANGE
Cash From Operating Activities	-3.456M	-4.160M	-16.76M
Cash From Investing Activities	-10.00K	-10.00K	-19.00K
Cash From Financing Activities	3.049M	2.930M	15.79M
Net Change In Cash	-417.0K	-1.240M	-987.0K
YoY Change	-79.12%	-55.71%	56.17%
FREE CASH FLOW
Cash From Operating Activities	-$3.456M	-$4.160M	-$16.76M
Capital Expenditures	$10.00K	-$10.00K	$19.00K
Free Cash Flow	-$3.466M	-$4.150M	-$16.78M
YoY Change		30.5%	15.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	204000
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	204000
CY2018Q4	us-gaap	Goodwill Goodwill	10845000
CY2017Q4	us-gaap	Goodwill Goodwill	10914000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2563000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3550000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	717000
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	696000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	3280000
CY2017Q4	us-gaap	Assets Current AssetsCurrent	4246000
CY2018Q4	us-gaap	Assets Assets	14723000
CY2017Q4	us-gaap	Assets Assets	15978000
CY2018Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	3221000
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1183000
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	457000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1696000
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2162000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2879000
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5840000
CY2018Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0
CY2017Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1000
CY2018Q4	us-gaap	Liabilities Liabilities	2879000
CY2017Q4	us-gaap	Liabilities Liabilities	5841000
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	0
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	0
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14723000
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15978000
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	206409000
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	184139000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-194565000
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-174002000
CY2018	us-gaap	Revenues Revenues	153000
CY2017	us-gaap	Revenues Revenues	335000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12966000
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10243000
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7518000
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7567000
CY2018	us-gaap	Operating Expenses OperatingExpenses	20484000
CY2017	us-gaap	Operating Expenses OperatingExpenses	17810000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-20331000
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-17475000
CY2018	us-gaap	Interest Expense InterestExpense	186000
CY2017	us-gaap	Interest Expense InterestExpense	643000
CY2018	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1000
CY2017	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	34000
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.98
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19000
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-74000
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-9.32
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4126393
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1937161
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	8761000
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16310000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2818000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-18056000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	10137000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2973000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-20563000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	11844000
CY2018	us-gaap	Profit Loss ProfitLoss	-20563000
CY2017	us-gaap	Profit Loss ProfitLoss	-18056000
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	231000
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	246000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	2973000
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	2818000
CY2018	pulm	Fair Value Adjustment On Derivative Liability FairValueAdjustmentOnDerivativeLiability	-1000
CY2017	pulm	Fair Value Adjustment On Derivative Liability FairValueAdjustmentOnDerivativeLiability	-34000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	21000
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	119000
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	726000
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-290000
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-221000
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	754000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16761000
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14477000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19000
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	74000
CY2018	pulm	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	19297000
CY2018	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	-3259000
CY2017	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	-2695000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15793000
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13919000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-987000
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-632000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3550000
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4182000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2563000
CY2018Q4	pulm	Working Capital Deficit WorkingCapitalDeficit	400000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2018Q4	us-gaap	Prepaid Insurance PrepaidInsurance	243000
CY2017Q4	us-gaap	Prepaid Insurance PrepaidInsurance	203000
CY2018Q4	pulm	Prepaid Clinical Trials PrepaidClinicalTrials	419000
CY2017Q4	pulm	Prepaid Clinical Trials PrepaidClinicalTrials	421000
CY2018Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	27000
CY2017Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	44000
CY2017Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	1000
CY2018Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	28000
CY2017Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	27000
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	35000
CY2017Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	3000
CY2017Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3221000
CY2018Q4	pulm	Debt Instrument Accretion Of Debt Discount DebtInstrumentAccretionOfDebtDiscount	35000
CY2018	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3000
CY2018Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	59000
CY2017Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	57000
CY2018Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	915000
CY2017Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1113000
CY2018Q4	pulm	Accrued Clinical And Consulting Current AccruedClinicalAndConsultingCurrent	517000
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2017Q4	pulm	Accrued Clinical And Consulting Current AccruedClinicalAndConsultingCurrent	568000
CY2018Q4	pulm	Accrued Legal And Patent Current AccruedLegalAndPatentCurrent	67000
CY2017Q4	pulm	Accrued Legal And Patent Current AccruedLegalAndPatentCurrent	61000
CY2017Q4	pulm	Accrued End Of Term Fee AccruedEndOfTermFee	225000
CY2018Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	67000
CY2017Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	68000
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	71000
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	70000
CY2018Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	3014000
CY2018	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y11M19D
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2510000
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3484000
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2116000
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2870000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	394000
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	614000
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	231000
CY2017	us-gaap	Depreciation And Amortization DepreciationAndAmortization	246000
CY2018Q4	us-gaap	Disposal Group Including Discontinued Operation Property Plant And Equipment DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment	993000
CY2017Q4	us-gaap	Disposal Group Including Discontinued Operation Property Plant And Equipment DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment	47000
CY2018	us-gaap	Depreciation And Amortization Discontinued Operations DepreciationAndAmortizationDiscontinuedOperations	985000
CY2017	us-gaap	Depreciation And Amortization Discontinued Operations DepreciationAndAmortizationDiscontinuedOperations	47000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	676000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	698000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1374000
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4703517
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	706589
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	2973000
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	2805000
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	369619
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	56.92
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	674104
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.68
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	71150
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	13.92
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	972573
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	23.85
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y5M16D
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	516.087
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	36.31
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y10M2D
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	959929
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	24.04
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y5M12D
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	149374000
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	99230000
CY2018Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	37640000
CY2017Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	32820000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3170000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2789000
CY2017	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	12000
CY2018Q4	pulm	Deferred Tax Assets Deferred Expense Capitalized Startup DeferredTaxAssetsDeferredExpenseCapitalizedStartup	851000
CY2017Q4	pulm	Deferred Tax Assets Deferred Expense Capitalized Startup DeferredTaxAssetsDeferredExpenseCapitalizedStartup	983000
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	520000
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	472000
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	44770000
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	38969000
CY2018Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	44770000
CY2017Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	38969000
CY2018Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0
CY2017Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.062
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.050
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.019
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.009
CY2018	pulm	Effective Income Tax Rate Reconciliation Nondeductible Expense Interest EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterest	0.000
CY2017	pulm	Effective Income Tax Rate Reconciliation Nondeductible Expense Interest EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterest	-0.001
CY2018	pulm	Effective Income Tax Rate Reconciliation Nondeductible Expense Permanent Differences EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferences	-0.006
CY2017	pulm	Effective Income Tax Rate Reconciliation Nondeductible Expense Permanent Differences EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferences	-0.003
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.003
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.031
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.282
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.613
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	69000
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	22000
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	28000
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-232000
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-581000
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	69000
CY2017	pulm	Noncash Rent Expense NoncashRentExpense	21000
CY2018	pulm	Non Cash Interest Expenses NonCashInterestExpenses	35000
CY2017	pulm	Non Cash Interest Expenses NonCashInterestExpenses	171000
CY2018	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	3000
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-8000
CY2017	pulm	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	16310000
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	304000
CY2018	pulm	End Of Term Loan Payments EndOfTermLoanPayments	-245000
CY2018	us-gaap	Interest Paid Net InterestPaidNet	131000
CY2017	us-gaap	Interest Paid Net InterestPaidNet	472000
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	19297000
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	304000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.977
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2589000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1905000
CY2018Q4	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2162000
CY2018	pulm	Cash Restricted For Letter Of Credit CashRestrictedForLetterOfCredit	153000
CY2018Q4	us-gaap	Deposits Money Market Deposits DepositsMoneyMarketDeposits	51000
CY2017	pulm	Cash Restricted For Letter Of Credit CashRestrictedForLetterOfCredit	153000
CY2017Q4	us-gaap	Deferred Tax Liabilities Undistributed Foreign Earnings DeferredTaxLiabilitiesUndistributedForeignEarnings	0
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4932723
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2104750
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4932723
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2104750
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3700000
CY2018	dei	Document Period End Date DocumentPeriodEndDate	2018-12-31
CY2018	dei	Entity Central Index Key EntityCentralIndexKey	0001574235
CY2018	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5801000
CY2018	pulm	Operating Loss Carryforwards Expiration Date Description OperatingLossCarryforwardsExpirationDateDescription	Various dates from 2023 through 2038.
CY2018	pulm	Deferred Tax Assets Tax Credit Carryforwards Expiration Date Description DeferredTaxAssetsTaxCreditCarryforwardsExpirationDateDescription	Various dates from 2022 through 2038.
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2018	pulm	Milestone Payments MilestonePayments	0
CY2018Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0
CY2018Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue	0
CY2018Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	0
CY2018	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0
CY2018	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	3259000
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3000
CY2018Q4	pulm	Accrued End Of Term Fee AccruedEndOfTermFee	0
CY2018	dei	Document Type DocumentType	10-K
CY2018	dei	Amendment Flag AmendmentFlag	false
CY2018	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2018	dei	Entity Registrant Name EntityRegistrantName	Pulmatrix, Inc.
CY2018	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2018	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2018	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2018Q2	dei	Entity Public Float EntityPublicFloat	17229294
CY2018	dei	Trading Symbol TradingSymbol	PULM
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2018	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2018	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8027895
CY2017	pulm	Decrease In Deferred Tax Assets DecreaseInDeferredTaxAssets	17600000
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	17600000
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1172000
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	59000
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	122000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1109000
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	115000
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	20000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1244000
CY2018	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10pt; color:#000000; font-family:'times new roman'; font-style:normal; font-variant-ligatures:normal; font-variant-caps:normal; font-weight:400; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin-top:12pt; margin-bottom:0pt"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates</div></div></div><div style="color: rgb(0, 0, 0); font-family: 'times new roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;">In preparing consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results may differ from these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payments, estimating the useful lives of depreciable and amortizable assets, valuation allowance against deferred tax assets, goodwill impairment, and estimating the fair value of long-lived assets to assess whether impairment charges may apply.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="color: rgb(0, 0, 0); font-family: 'times new roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Concentrations of Credit Risk</div></div></div><div style="font-size:10pt; color:#000000; font-family:'times new roman'; font-style:normal; font-variant-ligatures:normal; font-variant-caps:normal; font-weight:400; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin-top:6pt; margin-bottom:0pt"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cash is a financial instrument that potentially subjects the Company to concentrations of credit risk. For all periods presented, substantially all of the Company’s cash was deposited in an account at a single financial institution that management believes is creditworthy. The Company is exposed to credit risk in the event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits. The Company maintains its cash at a high-quality financial institution and has not incurred any losses to date.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Files In Submission

Name	View Source	Status
0001193125-19-043624-index-headers.html	Edgar Link	pending
0001193125-19-043624-index.html	Edgar Link	pending
0001193125-19-043624.txt	Edgar Link	pending
0001193125-19-043624-xbrl.zip	Edgar Link	pending
d680911d10k.htm	Edgar Link	pending
d680911dex1014.htm	Edgar Link	pending
d680911dex231.htm	Edgar Link	pending
d680911dex311.htm	Edgar Link	pending
d680911dex312.htm	Edgar Link	pending
d680911dex321.htm	Edgar Link	pending
d680911dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pulm-20181231.xml	Edgar Link	completed
pulm-20181231.xsd	Edgar Link	pending
pulm-20181231_cal.xml	Edgar Link	unprocessable
pulm-20181231_def.xml	Edgar Link	unprocessable
pulm-20181231_lab.xml	Edgar Link	unprocessable
pulm-20181231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PULM
Pulmatrix Inc Stock $pulm

2019 Q1 Form 10-K Financial Statement

#000119312519043624 Filed on February 19, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PULM Pulmatrix Inc Stock $pulm

2019 Q1 Form 10-K Financial Statement

#000119312519043624 Filed on February 19, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PULM
Pulmatrix Inc Stock $pulm